Recombinant Respiratory Syncytial Viruses with T-Cell Response Region Deleted Show Reduced Pulmonary Eosinophilia

Strategic Insights -

Researchers have engineered recombinant respiratory syncytial viruses (RSVs) with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. This modification aims to elicit a balanced immune response, reducing the risk of exaggerated respiratory tract disease and unwanted inflammation in the airways. The recombinant viruses, rA2cpΔG150-222 and rA2cpΔG177-220, were constructed and characterized in human lung epithelial cell lines and BALB/c mice, demonstrating similar replication rates and eliciting neutralizing antibody responses. Importantly, the deletion of the T-cell response region was shown to significantly diminish pulmonary eosinophilia in primed mice, making these viruses promising candidates for attenuated RSV vaccines.

Key Takeaways:

  • The recombinant RSV strains, rA2cpΔG150-222 and rA2cpΔG177-220, had a similar synthesis of nascent genomes in human lung epithelial cell lines compared to the parent virus.
  • Both rRSV strains replicated in the respiratory tracts of BALB/c mice and elicited serum neutralization and anti-F-protein immunoglobulin G titers equivalent to those elicited by the parent virus.
  • Pulmonary eosinophilia was significantly diminished in BALB/c mice primed with native G protein and challenged with either rA2cpΔG150-222 or rA2cpΔG177-220.
  • The deletion of the T-cell response region from the attachment (G) protein reduced the risk of exaggerated respiratory tract disease and unwanted inflammation in the airways.
  • The recombinant viruses may serve as promising candidates for attenuated RSV vaccines.

Statistics:

  • The rRSV strains fabricated 3.9-log10-unit reduction in RSV A2 levels 4 days after challenge in BALB/c mice.
  • The synthesis of nascent rRSV genomes in human lung epithelial cell lines was similar to that for the parent virus, with quantitative PCR demonstrating no significant difference.
  • The replication of both rRSV strains in the respiratory tracts of BALB/c mice resulted in equivalent neutralizing antibody responses compared to the parent virus.
  • The 3.9-log10-unit reduction in RSV A2 levels 4 days after challenge is a significant improvement over the parent virus.

Sources:

  • Elliot, M. B., et al. "Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein." Journal of Virology, vol. 78, no. 16, 2004, pp. 8446-8454.
  • Hancock, G. E., Department of Immunology, Wyeth Vaccines Research, 401 North Middletown Road, Pearl River, NY 10965, USA. E-mail: hancocg@wyeth.com.
  • American Society for Microbiology, 1752 N Street NW, Washington, DC 20036-2904, USA.